z-logo
open-access-imgOpen Access
Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors
Author(s) -
Mansour Poorebrahim,
Mohammad Foad Abazari,
Leila Moradi,
Behzad Shahbazi,
Reza Mahmoudi,
Hourieh Kalhor,
Hasan Askari,
Ladan TeimooriToolabi
Publication year - 2022
Publication title -
plos computational biology/plos computational biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.628
H-Index - 182
eISSN - 1553-7358
pISSN - 1553-734X
DOI - 10.1371/journal.pcbi.1009962
Subject(s) - kras , small molecule , mutant , cancer research , oncogene , biology , peptide , cancer , mutation , in vivo , chemistry , gene , microbiology and biotechnology , genetics , biochemistry , cell cycle
K-Ras activating mutations are significantly associated with tumor progression and aggressive metastatic behavior in various human cancers including pancreatic cancer. So far, despite a large number of concerted efforts, targeting of mutant-type K-Ras has not been successful. In this regard, we aimed to target this oncogene by a combinational approach consisting of small peptide and small molecule inhibitors. Based on a comprehensive analysis of structural and physicochemical properties of predominantly K-Ras mutants, an anti-cancer peptide library and a small molecule library were screened to simultaneously target oncogenic mutations and functional domains of mutant-type K-Ras located in the P-loop, switch I, and switch II regions. The selected peptide and small molecule showed notable binding affinities to their corresponding binding sites, and hindered the growth of tumor cells carrying K-Ras G12D and K-Ras G12C mutations. Of note, the expression of K-Ras downstream genes (i.e., CTNNB1, CCND1) was diminished in the treated Kras-positive cells. In conclusion, our combinational platform signifies a new potential for blockade of oncogenic K-Ras and thereby prevention of tumor progression and metastasis. However, further validations are still required regarding the in vitro and in vivo efficacy and safety of this approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here